Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study
J Nephrol
.
2014 Dec;27(6):717.
doi: 10.1007/s40620-014-0128-2.
Authors
Matteo Ruggeri
1
,
Antonio Bellasi
2
3
,
Filippo Cipriani
4
,
Donald Molony
5
,
Cynthia Bell
6
,
Domenico Russo
7
,
Biagio Di Iorio
8
Affiliations
1
Faculty of Economics, Università Cattolica del Sacro Cuore, Rome, Italy.
2
Division of Nephrology, Sant'Anna Hospital, Como, Italy.
3
Department of Health Sciences, University of Milan, Milan, Italy.
4
Market Access and Corporate Affairs, Genzyme, Italy.
5
Division of Renal Dis and Hypertension, Department of Medicine, University of Texas Houston Medical School, Houston, TX, USA.
6
Division of Pediatric Nephrology, Department of Pediatrics, University of Texas Houston Medical School, Houston, TX, USA.
7
Department of Nephrology, School of Medicine, Federico II University, Naples, Italy.
8
Department of Nephrology, Ospedale A. Landolfi di Solofra, Solofra (AV), Italy.
[email protected]
.
PMID:
25098354
DOI:
10.1007/s40620-014-0128-2
No abstract available
Publication types
Published Erratum